

# LSMO

Lebanese Society of Medical Oncology  
الجمعية اللبنانية لأطباء الأورام الخبيث



# 17<sup>TH</sup> LSMO

## THE 17<sup>TH</sup> LEBANESE SOCIETY OF MEDICAL ONCOLOGY NATIONAL FORUM

June 4 - 6, 2020 | LIVE WEBINAR SESSIONS

*in collaboration with:*





## WELCOME LETTER



On behalf of the LSMO Organizing Committee, it gives me great pleasure to invite you all to participate in the "17<sup>th</sup> Lebanese Society of Medical Oncology National Forum," as a Webinar meeting divided in different sessions and in different days.

Despite all the dreadful events that are taking place in Lebanon, such as the current outbreak of coronavirus disease (COVID-19) and the economic crisis, we are delighted and content that you were able to make it to 17<sup>th</sup> Lebanese Society of Medical Oncology National Forum. Many people worked to bring this event into reality, and I want to thank them all. Our mission has been and will continue to be dedicated to the passionate pursuit of improving the cancer care of the community in Lebanon and the region through the delivery of excellence in continuous medical education.

The scientific program contains a series of high-profile plenary presentations, symposia, and concurrent sessions. This gathering will focus on bringing together the opportunity to learn about novelties & actual tendencies of Hematology and Oncology. We aim to bridge gaps and pave the future by hosting several speakers from Europe and the region who will be giving lectures on the recent updates in breast cancer, lung cancer, melanoma, GI, and GU malignancies as well as malignant hematology, and many more.

I am convinced, the program will provide you with new information, better knowledge, provide ideas on how to improve your research and results and it will be a stimulus to further harmonize our medical standards and to successfully compete with our neighboring disciplines. Looking forward to a successful and fruitful congress and hoping to see you all there!

**Nizar Bitar, MD**  
LSMO President



## COMMITTEES

### EXECUTIVE BOARD

**President**

Nizar Bitar, MD

**Past President**

Joseph Makdessi, MD

**President Elect**

Roger Khater, MD

**General Secretary**

Oussama Jradi, MD

**Treasurer**

Therese Abou Nasr, MD

**Members**

Hanane Yassine, MD

Mohamad Haidar, MD

Naji Amro, MD

Rita Murr, MD

Walid Moukadem, MD

### SCIENTIFIC COMMITTEE

**President**

Nizar Bitar, MD

**Members**

Hazem Assi, MD

Rita Assi, MD

Georges El Hashem, MD

Fadi El Karak, MD

Joseph Kattan, MD

Joseph Makdessi, MD

Marcel Massoud, MD

Ali Shamseddine, MD



**THURSDAY, JUNE 4, 2020**

**PM**

**13:45 - 14:00 Introduction and Welcome Note**

**14:00 - 18:25 LUNG**

14:00 - 14:15 Screening for the Deadliest Cancer: Barriers / Role of Societies Imad Bou Akl, MD

14:15 - 14:30 Counseling our Patients on E- cigarettes and Thoracic Malignancies Zeina Aoun, MD

14:30 - 14:45 How to accurately Stage the Mediastinum for Stage III Non-Small Cell Lung Carcinoma in the Era of Immunotherapy Jamil Borgi, MD

14:45 - 15:15 Hallmarks of IO Combination Therapy  
**BMS Symposium** Georges Chahine, MD

15:15 - 15:45 Updates in NTRK Fusion Positive Disease  
**Roche Symposium** Hazem Assi, MD

15:45 - 16:00 Management Of Lung and Breast Cancer Patients During COVID 19 Pandemic  
**Lecture Sponsored by Roche** Arafat Tfayli, MD

**16:00 - 16:10 BREAK**

16:10 - 16:25 Immunotherapy for Small Cell Lung Cancer: Lebanese Real World Data Fadi El Karak, MD

16:25 - 16:40 Management of Rare Mutations in Non-Small Cell Lung Carcinoma Arafat Tfayli, MD

16:40 - 16:55 How Should Immunotherapy with PD-1 Inhibitors be Integrated Into the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma? Ghazi Nsouli, MD

16:55 - 17:25 Pembrolizumab, Redefining Survival Expectations as a Frontline Treatment for mNSCLC  
**MSD Symposium** Joseph Makdessi, MD

17:25 - 17:55 Imfinzi: A New Standard of Care in Management of Stage III Unresectable Non-Small Cell Lung Carcinoma Patients  
**Astra Zeneca Symposium** Fadi Nasr, MD

17:55 - 18:25 Immune Checkpoint Inhibitors in Head and Neck Cancer: Evolving Treatment Landscape and Current Evidence  
**BMS Symposium** Fadi Farhat, MD



**FRIDAY, JUNE 5, 2020**

**AM**

<b>10:00 - 12:55 HEMATOLOGY</b>		
10:00 - 10:15	Latest Breakthroughs in Hodgkin's Lymphoma: Celebrating 200 Years Since Thomas Hodgkin	Hady Ghanem, MD
10:15 - 10:30	Optimal Induction Therapy for Multiple Myeloma: What to Use in the Era of Monoclonal Antibodies	Rita Assi, MD
10:30 - 11:00	<b>Moderator: Colette Hanna, MD</b> On the Front Line: Managing Patients with the CD30+ HL <b>Takeda Symposium</b>	Jean Al Cheikh, MD
11:00 - 11:30	<b>Moderator: Nizar Bitar, MD</b> 25 Years Awaiting Breakthrough Innovation in AML - Rydapt <b>Novartis Symposium</b>	Ahmad Ibrahim, MD
<b>11:30 - 11:40 BREAK</b>		
11:40 - 12:10	New ERA in Philadelphia Positive Leukemia <b>Biologix Symposium</b>	Ali Bazarbachi, MD
12:10 - 12:25	Personalized Treatment of Chronic Lymphocytic Leukemia: Shifting Standard of Care for Frontline therapy	Marcel Massoud, MD
12:25 - 12:55	<b>Moderator: Nizar Bitar, MD</b> New ITP ASH Guidelines <b>Novartis Symposium</b>	Ali Taher, MD



**FRIDAY, JUNE 5, 2020**

**PM**

<b>14:00 - 18:50 BREAST</b>		
14:00 - 14:30	<b>Moderator: Hazem Assi, MD</b> Standing out of the Crowd: Along the mBC Journey- Explore Verzenio (Abemaciclib) <b>Lilly Symposium</b>	Joseph Kattan, MD
14:30 - 14:45	Partial Breast Radiation Therapy: Which Patients, When, and With What Technique?	Caroline Samaha, MD
14:45 - 15:00	Optimal Adjuvant and Neo-adjuvant Therapy in HER-2+ Patients	Nagi El Saghir, MD
15:00 - 15:30	Atezolizumab in Metastatic TNBC; Keep Patients Connected to life <b>Roche Symposium</b>	Haifa Dbouk, MD
<b>15:30 - 15:40 BREAK</b>		
15:40 - 16:20	KISQALI - The Difference is More LIFE <b>Novartis Symposium</b>	Georges Chahine, MD Ghazi Nsouli, MD
16:20 - 16:40	The Role of PIK3CA Inhibitors In the Management of HR+ HER2- ABC <b>Novartis Symposium</b>	Fadi Farhat, MD
16:40 - 17:10	<b>Moderator: Nizar Bitar, MD</b> The Role of Biosimilars in Breast Cancer; "Behind Kanjinti a Robust Totality of Evidence" <b>Amgen Symposium</b>	Nagi El Saghir, MD
17:10 - 17:40	Managing Chronic Pain: The Era of TARGINACT <b>Mundipharma Symposium</b>	Rana Yamout, MD Fadi Nasr, MD
<b>17:40 - 17:50 BREAK</b>		
17:50 - 18:05	Selecting Patients for Immunotherapy - PDL1 and Beyond	Hazem Assi, MD
18:05 - 18:20	Management Options after Progression on CDK 4/6 Inhibitors	Marwan Ghosn, MD
18:20 - 18:50	From Clinical Trials to Practice: Blazing the Trail in the Treatment of Breast Cancer <b>Pfizer Symposium</b>	Anthony Saroufim, MD Hady Ghanem, MD



**SATURDAY, JUNE 6, 2020**

**AM**

**10:00 - 13:25 GENITOURINARY**

10:00 - 10:15	Radiotherapy and its Timing in Adjuvant Prostate Cancer Treatment	Fadi Geara, MD
10:15 - 10:30	Sequential New Anti-Androgens or Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer	Joseph Makdessi, MD
10:30 - 10:45	Non-Muscle Invasive Bladder Cancer: Are all Patients the Same?	Elie Nemr, MD
10:45 - 11:00	Immunotherapy after Bacillus Calmette-Guerin Failure in Non-Muscle Invasive Bladder Cancer	Joseph Kattan, MD
11:00 - 11:15	Combination First - Line Therapy in Metastatic Renal Cell Carcinoma	Sally Tamraz, MD

11:15 - 11:45	Immunotherapy in First Line Renal Cell Carcinoma: A Shift in Treatment Paradigm <b>BMS Symposium</b>	Hady Ghanem, MD
---------------	---	-----------------

**11:45 - 11:55 BREAK**

11:55 - 12:25	<b>Moderator: Nizar Bitar, MD</b> Rethinking mHSPC: What Do We Need to Debate? <b>Janssen Symposium</b>	Ali Shamseddine, MD
---------------	---	---------------------

12:25 - 12:55	Role of Pembrolizumab in Metastatic Urothelial Carcinoma <b>MSD Symposium</b>	Colette Hanna, MD
---------------	--	-------------------

12:55 - 13:25	The Real-World Evidence of Chemotherapy in Metastatic Urothelial Carcinoma <b>Pierre Fabre Symposium</b>	Joaquim Bellmunt, MD
---------------	---	----------------------

**SATURDAY, JUNE 6, 2020**

**PM**

**14:00 - 15:30 GASTROENTEROLOGY**

14:00 - 14:15	Are Molecular Markers for Colon Cancer Ready for Prime Time?	Hampig Kourie, MD
14:15 - 14:30	FLOT or not- Revisiting the Current and Future role of Radiotherapy in Gastroesophageal Junction Cancers	Youssef Zeidan, MD

14:30 - 15:00	<b>Moderator: Nizar Bitar, MD</b> Importance of Treatment Sequence in Gastric Cancer <b>Lilly Symposium</b>	Marwan Ghosn, MD
---------------	---	------------------

15:00 - 15:15	The Role of Immunotherapy in Metastatic Colorectal Cancer	Ali Shamseddine, MD
---------------	---	---------------------

15:15 - 15:30	The Role of PRRT in the Management of NET	Mohammad Haidar, MD
---------------	---	---------------------

The **Lebanese Society of Medical Oncology (LSMO)**  
 would like to thank the following companies  
 for their contribution to the success of its annual congress



**Bristol-Myers Squibb**



**MSD**  
 INVENTING FOR LIFE



**NOVARTIS**



**Biologix** FZCO  
 serviced by: Algorithm SAL



**AMGEN**



**astellas**

**AstraZeneca**  
 What science can do

**SANOFI**



**Pierre Fabre**  
 Oncology

**MERCK**



**ABELA**  
 MARKETING ME

**Boehringer**  
 Ingelheim

**IPSGenomix**  
 Committed to Progress of Software

**SANDOZ** A Novartis  
 Division

**NEWBRIDGE**  
 PHARMACEUTICALS

Organized by:  
  
**Infomed**  
 INTERNATIONAL FOR EVENTS

**LEBANON**

4<sup>th</sup> Floor, Qubic Center  
 Daoud Ammoun Street  
 Horsh Tabet - Sin El Fil  
 P.O. Box 90-361 Beirut  
 Tel: +961 1 510880/1/2/3  
 Mobile: +961 71 103123

**UAE**

DMCC Business Centre  
 Almas Tower  
 Jumeirah Lakes  
 Dubai, United Arab Emirates  
 Unit No: 3820  
 Mobile: +971 50 9110475

**KUWAIT**

Mezzanine floor,  
 Aliya Complex  
 Salem Al Mubarak St  
 Block 2, Salmiya - Kuwait  
 Tel: +965 6556 7669



infomed@infomedweb.com | www.infomedweb.com